Related MeSH Hierarchy (8)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Urologic Neoplasms » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Urologic Neoplasms » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Urinary Bladder Diseases » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urogenital Neoplasms » Urologic Neoplasms » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Urinary Bladder Diseases » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Urologic Neoplasms » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Urinary Bladder Diseases » Urinary Bladder Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Urologic Neoplasms » Urinary Bladder Neoplasms
Description
Tumors or cancer of the URINARY BLADDER. MeSH
Hierarchy View
Phase 4 Indicated Drugs (31)
Phase 3 Indicated Drugs (59)
Phase 2 Indicated Drugs (145)
autologous dendritic cells primed with muc-1/wt-1 peptides
autologous hematopoietic stem cells
autologous T cell memory cells
bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)
Phase 1 Indicated Drugs (94)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
anti-ny eso-1 tcr-transduced t cells
dec-205/ny-eso-1 fusion protein cdx-1401
hepatitis a vaccine, inactivated (vaqta)
Other Experimental Indicated Drugs (17)
Organization Involved with Phase 4 Indications (14)
Organization Involved with Phase 3 Indications (131)
Association of Urogenital Oncology (AUO)
Australasian Gastro-Intestinal Trials Group
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Azienda Ospedaliera San Camillo Forlanini
Canadian Institutes of Health Research (CIHR)
Cancer and Leukemia Group B (CALGB)
Central European Cooperative Oncology Group
Chinese Academy of Medical Sciences
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
German Association of Urologic Oncology
Groupe D'Etude des Tumeurs Uro-Genitales
Handok Pharmaceuticals Co., Ltd.
Jiangsu Asieris Pharmaceutical Technology Co., Ltd.
Katholieke Universiteit Leuven
Klinikum Nuernberg - Klinikum Nord
KWF Kanker Bestrijding The Netherlands
Medical Enterprises Europe B.V.
National Health and Medical Research Council, Australia
National University of Singapore
Oregon Health and Science University
People's Liberation Army of China
Princess Al-Johara Al-Ibrahim Cancer Research Center
Samyang Biopharmaceuticals Corporation
Society of Urologic Oncology Clinical Trials Consortium
Spanish Oncology Genito-Urinary Group
Swiss Group for Clinical Cancer Research
Trans Tasman Radiation Oncology Group
Universidad Autonoma de Barcelona
Organization Involved with Phase 2 Indications (197)
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
Azienda Ospedaliera San Giovanni Battista
Azienda Ospedaliero-Universitaria Consorziale
Beijing Huanxing Cancer Hospital
Belarusian State Medical University
Campania Younger Oncologists Association
Cancer Immunotherapy Trials Network
Case Western Reserve University
Centre Georges Francois Leclerc
Centro Integral Oncológica Clara Campal
City of Hope National Medical Center
European Association of Urology Research Foundation
Fundacion CRIS de Investigación para Vencer el Cáncer
Fundación para la Investigación en Urología (FIU)
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Gottfried Wilhelm Leibniz Universität Hannover
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Hamilton Health Sciences Corporation
Hellenic GenitoUrinary Cancer Group
Hellenic Oncology Research Group
Herbert Irving Comprehensive Cancer Center
Hoosier Cancer Research Network
Hospital Universitario Basurto
Icahn School of Medicine at Mount Sinai
Instituto Catalán de Oncología Badalona
Instituto Catalán de Oncología L'Hospitalet
James and Esther King Biomedical Research Program
Latin American Cooperative Oncology Group
Medical University of South Carolina
National Academy of Sciences of Belarus
National Comprehensive Cancer Network
National Institute for Health Research, United Kingdom
National Institutes of Health (NIH)
North Florida Foundation for Research and Education
Ontario Institute for Cancer Research
Pharmaceutical Research Associates, Inc. (PRA)
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Shenzhen Geno-Immune Medical Institute
Shijiazhuang Pharma Group (CSPC)
Technical University of Munich
The First People's Hospital of Changzhou
Organization Involved with Phase 1 Indications (57)
Adlai Nortye Biopharma Co., Ltd.
Badalona Hospital Germans Trias i Pujol
Guangdong Xiangxue Precision Medical Technology Co., Ltd
Guangzhou Xiangxue Pharmaceutical Co., Ltd
Lawrence Livermore National Laboratory
Organization Involved with Other Experimental Indications (12)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
